Journal of Neonatal Surgery
ISSN(Online): 2226-0439
Vol.15 , Issue 1s (2026)
https://www.jneonatalsurg.com

OPEN ACCESS

Cardio Oncologic Complexity in Gynecological Malignancies: Integrating Nuclear Radiation Therapy, Chemotherapy, and Radical Surgery in Pacemaker Dependents Patients

Ayan Goswami

Assistant Professor Affiliation: Barasat College of Pharmaceutical Science and Research Centre

Email: agoswami.pharmacy@gmail.com

ORCID ID: _0009-0005-9642-0695

Corresponding Author:

Ayan Goswami

Cite this paper as: Ayan Goswami (2026) Cardio Oncologic Complexity in Gynecological Malignancies: Integrating Nuclear Radiation Therapy, Chemotherapy, and Radical Surgery in Pacemaker Dependents Patients. Journal of Neonatal Surgery, 15, (1s) 166-179

ABSTRACT

Background: The management of gynecological malignancies has become increasingly complex in patients who are pacemaker-dependent due to the potential cardiovascular risks associated with chemotherapy, radiation therapy, and radical surgical procedures. These treatment modalities, while essential for cancer control, may adversely affect cardiac function or interfere with the performance of cardiac implantable electronic devices, requiring careful multidisciplinary planning.

Objective: This review aims to summarize the current evidence on the multidisciplinary management of pacemaker-dependent patients with gynecological malignancies, with a particular focus on the integration of nuclear radiation therapy, chemotherapy, and radical surgery. It also highlights the challenges, safety considerations, and recent advances in cardio-oncology that support optimal treatment outcomes.

Methods: A comprehensive review of the published literature was performed using peer-reviewed articles, clinical practice guidelines, systematic reviews, and observational studies focusing on gynecological cancers, cardio-oncology, pacemaker management, radiation oncology, chemotherapy-induced cardiotoxicity, and perioperative care. Relevant evidence was critically analyzed to provide an updated overview of current clinical practice.

Results: Available evidence suggests that successful treatment of gynecological malignancies in pacemaker-dependent patients requires individualized risk assessment, careful radiation planning, continuous cardiac monitoring, appropriate pacemaker management, and close collaboration among gynecologic oncologists, cardiologists, radiation oncologists, medical oncologists, anesthesiologists, and electrophysiologists. Modern radiotherapy techniques, advancements in cardiac device technology, and standardized monitoring protocols have significantly reduced treatment-related complications while improving patient safety and clinical outcomes.

Conclusion: The integration of nuclear radiation therapy, chemotherapy, and radical surgery in pacemaker-dependent patients presents unique clinical challenges that demand a multidisciplinary cardio-oncology approach. Early cardiovascular evaluation, personalized treatment planning, and adherence to evidence-based guidelines are essential to minimize complications and optimize both oncological and cardiac outcomes. Further prospective studies and standardized clinical recommendations are needed to strengthen evidence-based management strategies for this high-risk patient population

Keywords: Cardio-oncology, Gynecological malignancies, Pacemaker-dependent patients, Radiation therapy, Chemotherapy, Radical surgery, Cardiotoxicity, Multidisciplinary care

INTRODUCTION

1.1 Overview of Gynecological Malignancies

Gynecological malignancies comprise a diverse group of cancers arising from the female reproductive system, including cervical, ovarian, endometrial, vulvar, and vaginal cancers. These diseases differ in their incidence, biological behavior, prognosis, and therapeutic approaches. [1] Advances in screening programs, imaging techniques, molecular diagnostics, and multimodal treatment strategies have significantly improved patient survival. However, successful management requires individualized treatment planning based on tumor characteristics, disease stage, and the patient's overall health status. [2]



Image: 1 Gynecological Malignancies

1.2 Burden and Global Epidemiology

Gynecological cancers represent a major global health challenge and account for a considerable proportion of cancer-related morbidity and mortality among women. [3] Cervical cancer remains one of the most common malignancies in low- and middle-income countries due to limited screening and vaccination coverage. .[4] Ovarian cancer is associated with the highest mortality because it is often diagnosed at an advanced stage, whereas the incidence of endometrial cancer continues to rise owing to increasing obesity, diabetes, and aging populations. These trends highlight the need for improved prevention, early diagnosis, and multidisciplinary management.[5]

1.3 Concept of Cardio-Oncology

Cardio-oncology is an emerging multidisciplinary specialty that focuses on preventing, detecting, and managing cardiovascular complications associated with cancer and its treatment. [6]

Many anticancer therapies, including chemotherapy, radiotherapy, targeted therapy, and immunotherapy, may adversely affect the cardiovascular system. The primary objective of cardio-oncology is to ensure that patients receive effective cancer treatment while minimizing treatment-related cardiac toxicity and preserving long-term cardiovascular health.[7-8]



Image: 2 Concept of Cardio-Oncology

1.4 Pacemaker-Dependent Patients in Cancer Care

The presence of a permanent pacemaker introduces additional complexity during cancer treatment. Radiation exposure may interfere with pacemaker function, certain chemotherapeutic agents may increase the risk of arrhythmias or myocardial dysfunction, and major surgical procedures require meticulous perioperative cardiac management. Consequently,

pacemaker-dependent patients require comprehensive cardiovascular evaluation before treatment, continuous monitoring during therapy, and regular device assessment throughout the treatment course.[9-10]

1.5 Rationale and Significance of the Review

Although substantial progress has been made in both gynecologic oncology and cardio-oncology, evidence specifically addressing the management of pacemaker-dependent patients with gynecological malignancies remains limited. Most available recommendations are extrapolated from broader cardio-oncology guidelines, emphasizing the need for a comprehensive review that integrates current evidence from oncology, cardiology, radiation oncology, and perioperative care. Such an approach may assist clinicians in optimizing treatment outcomes while minimizing cardiovascular complications.[11-12]

1.6 Objectives of the Review

The primary objective of this review is to summarize current evidence regarding the management of gynecological malignancies in pacemaker-dependent patients. Specifically, this review aims to:

- Describe the clinical characteristics and epidemiology of major gynecological malignancies.
- Discuss the principles of cardio-oncology in cancer care.
- Evaluate the cardiovascular effects of chemotherapy, radiation therapy, and radical surgery.
- Review strategies for pacemaker monitoring and multidisciplinary patient management.
- Highlight recent advances, current challenges, and future research directions in this evolving field.

2. Clinical Overview of Gynecological Malignancies

2.1 Cervical Cancer

Cervical cancer is one of the most common gynecological malignancies worldwide and is strongly associated with persistent infection by high-risk human papillomavirus (HPV). Common symptoms include abnormal vaginal bleeding, pelvic pain, and unusual vaginal discharge. Treatment depends on the stage of the disease and may include surgery, radiotherapy, chemotherapy, or a combination of these modalities.[13]

2.2 Ovarian Cancer

Ovarian cancer is the leading cause of death among gynecological cancers because it is often diagnosed at an advanced stage. Patients usually present with nonspecific symptoms such as abdominal bloating, pelvic discomfort, early satiety, and weight loss. Standard treatment consists of cytoreductive surgery followed by platinum-based chemotherapy.[14]

2.3 Endometrial Cancer

Endometrial cancer originates from the inner lining of the uterus and is commonly diagnosed after menopause. The most frequent symptom is abnormal uterine bleeding. Early-stage disease is generally managed with hysterectomy, while advanced cases may require chemotherapy, radiotherapy, or hormonal therapy.[15]

2.4 Vulvar and Vaginal Cancers

Vulvar and vaginal cancers are relatively uncommon compared with other gynecological malignancies. Risk factors include HPV infection, increasing age, smoking, and chronic inflammatory conditions. Management depends on tumor stage and location and may involve surgery, radiotherapy, chemotherapy, or combined treatment.[16]



Image: 3 Gynecological Cancer

2.5 Standard Treatment Modalities

The treatment of gynecological malignancies is individualized according to the cancer type, stage, and overall health of the patient.[17] The main treatment modalities include surgery, chemotherapy, radiation therapy, targeted therapy, and immunotherapy. In pacemaker-dependent patients, treatment planning should also consider cardiovascular safety and continuous monitoring of pacemaker function to minimize treatment-related complications.[18]

3. Cardio-Oncology and Pacemaker Dependency

3.1 Definition and Scope of Cardio-Oncology

Cardio-oncology is a specialized field that focuses on preventing, diagnosing, and managing cardiovascular complications associated with cancer and its treatment. Its main goal is to ensure that patients receive effective cancer therapy while maintaining optimal heart health and reducing treatment-related cardiac risks.[19-20]

3.2 Pacemaker: Types and Functions

A pacemaker is an implantable electronic device used to regulate abnormal heart rhythms. It delivers electrical impulses to maintain an adequate heart rate when the heart's natural conduction system fails. Depending on the patient's condition, pacemakers may be single-chamber, dual-chamber, or biventricular devices.[21]



Imag:4 Types of Pacemakers

3.3 Pacemaker-Dependent Patients

Pacemaker-dependent patients rely on continuous pacemaker function to maintain a stable heart rhythm. During cancer treatment, these patients require special attention because radiation therapy, chemotherapy, and major surgery may affect cardiac function or interfere with pacemaker performance. Careful monitoring throughout treatment is therefore essential.[22-23]

3.4 Cardiovascular Risk Assessment Before Cancer Therapy

Before initiating cancer treatment, a comprehensive cardiovascular evaluation should be performed. This includes medical history, physical examination, electrocardiography (ECG), echocardiography, and pacemaker interrogation. Early identification of cardiovascular risk factors allows clinicians to plan safer and more individualized treatment strategies.[24]

Table 1. Gynecological Malignancies and Standard Treatment

Cancer Type	Standard Treatment
Cervical Cancer	Surgery, Chemoradiotherapy, Brachytherapy
Ovarian Cancer	Cytoreductive Surgery + Carboplatin/Paclitaxel
Endometrial Cancer	Hysterectomy ± Radiotherapy ± Chemotherapy
Vulvar Cancer	Surgery ± Radiotherapy
Vaginal Cancer	Radiotherapy ± Surgery[25]

4. Pathophysiological Basis of Cardiovascular Complications

4.1 Mechanisms of Cardiotoxicity

Cancer treatment can affect the cardiovascular system through different mechanisms. Chemotherapy, radiation therapy, and targeted therapies may damage cardiac muscle cells, blood vessels, and the electrical conduction system of the heart. These changes may increase the risk of cardiotoxicity, especially in patients with pre-existing heart disease.[26]

4.2 Radiation-Induced Cardiac Injury

Radiation therapy may cause inflammation, fibrosis, and vascular damage when the heart or nearby structures are exposed to radiation. Although modern radiation techniques have reduced this risk, careful treatment planning is essential, particularly in pacemaker-dependent patients, to minimize radiation exposure to the device.[27]

4.3 Chemotherapy-Associated Cardiac Damage

Several anticancer drugs can impair cardiac function through oxidative stress, endothelial injury, and direct myocardial toxicity. These effects may lead to arrhythmias, reduced left ventricular function, hypertension, or heart failure. Early cardiac monitoring helps in the timely detection and management of these complications.[28]

4.4 Factors Increasing Cardiovascular Risk

The severity of cardiovascular complications depends on multiple factors, including patient age, pre-existing cardiovascular disease, diabetes, hypertension, cumulative drug dose, radiation exposure, and pacemaker dependency. Identifying these risk factors before treatment allows clinicians to develop safer and more individualized treatment plans.[29-30]

5. Nuclear Radiation Therapy in Pacemaker-Dependent Patients

5.1 Principles of Radiation Therapy

Radiation therapy is an important treatment modality for many gynecological malignancies. It destroys cancer cells by damaging their DNA while minimizing injury to surrounding healthy tissues. The choice of radiation technique depends on the type, stage, and location of the tumor.[31]

5.2 External Beam Radiation Therapy (EBRT)

External Beam Radiation Therapy (EBRT) delivers high-energy radiation from outside the body to the tumor site. It is commonly used in cervical, endometrial, and vaginal cancers. In pacemaker-dependent patients, careful treatment planning is necessary to reduce radiation exposure to the cardiac device.[32]

5.3 Brachytherapy

Brachytherapy involves placing a radioactive source close to or inside the tumor. It provides a high radiation dose directly to the cancer while limiting exposure to nearby normal tissues. This technique is frequently combined with EBRT in the treatment of cervical cancer.[33]

5.4 Radiation-Induced Pacemaker Malfunction

Radiation exposure may interfere with pacemaker function by causing temporary or permanent device malfunction. Potential complications include programming errors, battery depletion, loss of pacing, or inappropriate sensing. Therefore, regular pacemaker assessment is recommended during radiotherapy.[34]

5.5 Radiation Dose Limits and Safety Recommendations

Radiation dose to the pacemaker should be kept as low as reasonably achievable. Modern treatment planning techniques, accurate device localization, and adherence to established safety guidelines help reduce the risk of pacemaker-related complications during radiotherapy.[35]

5.6 Clinical Monitoring During Radiotherapy

Continuous monitoring is essential throughout radiation treatment. Pacemaker interrogation before and after therapy, ECG monitoring when indicated, and close collaboration between radiation oncologists, cardiologists, and medical physicists help ensure safe and effective treatment.[36]

6. Chemotherapy and Cardiovascular Complications

6.1 Common Chemotherapeutic Agents Used in Gynecological Malignancies

Cisplatin

Cisplatin is widely used in the treatment of cervical, ovarian, and endometrial cancers. Although highly effective, it may increase the risk of hypertension, thromboembolic events, and cardiac dysfunction in susceptible patients.[37]

Carboplatin

Carboplatin is commonly used as an alternative to cisplatin because of its better tolerability. However, cardiac monitoring is still recommended in patients with pre-existing cardiovascular disease.[38]

Paclitaxel

Paclitaxel is frequently combined with platinum-based chemotherapy for ovarian and endometrial cancers. It may cause bradycardia, arrhythmias, and changes in cardiac conduction, particularly during infusion.[39]

Doxorubicin

Doxorubicin is an anthracycline with well-recognized cardiotoxic effects. Long-term or high cumulative doses may lead to left ventricular dysfunction and heart failure.[40]

Bevacizumab

Bevacizumab is a targeted anti-angiogenic agent used in selected gynecological malignancies. Its major cardiovascular adverse effects include hypertension, thromboembolism, and, rarely, heart failure.[41]

6.2 Mechanisms of Cardiotoxicity

Chemotherapeutic agents may damage the heart through oxidative stress, endothelial injury, mitochondrial dysfunction, and direct myocardial toxicity. These mechanisms can impair cardiac function and increase the risk of cardiovascular complications.

6.3 Arrhythmias and Conduction Disorders

Certain anticancer drugs may alter the heart's electrical activity, resulting in bradycardia, tachycardia, atrial fibrillation, QT interval prolongation, or other conduction abnormalities. Pacemaker-dependent patients require careful rhythm monitoring throughout treatment.

6.4 Heart Failure and Left Ventricular Dysfunction

Cardiotoxic chemotherapy may reduce myocardial contractility, leading to left ventricular dysfunction and, in severe cases, heart failure. Early detection through echocardiography and cardiac biomarkers helps prevent irreversible cardiac damage.[42]

6.5 Cardiac Monitoring During Chemotherapy

Baseline cardiovascular evaluation should be performed before chemotherapy. Regular ECG, echocardiography, cardiac biomarker assessment, and periodic pacemaker interrogation are recommended to detect cardiac complications early and ensure safe continuation of cancer treatment.[43]

Table 2. Common Chemotherapeutic Agents and their Cardiotoxic Effect

Drug	Cardiotoxic Effect
Cisplastin	Arrhythmia, Hypertension, Electrolyte Imbalance
Carboplatin	Rare Arrhythmia
Paclitaxel	Bradycardia, Conduction abnormalities
Doxorubicin	Cardiomyopathy,HeartFailure
Bevacizumab	Hypertention,Thromboembolism[44]

7. Radical Surgery in Pacemaker-Dependent Patients

7.1 Radical Hysterectomy

Radical hysterectomy is the standard surgical treatment for patients with early-stage cervical cancer. The procedure involves removal of the uterus, cervix, upper vagina, and surrounding tissues. In pacemaker-dependent patients, preoperative cardiac assessment and pacemaker evaluation are essential to reduce perioperative risks.[45]

7.2 Cytoreductive (Debulking) Surgery

Cytoreductive surgery is the primary treatment for advanced ovarian cancer and aims to remove as much tumor tissue as possible. These procedures are often lengthy and require continuous ECG monitoring, careful fluid management, and regular assessment of pacemaker function.[46]

7.3 Pelvic Exenteration

Pelvic exenteration is a major surgical procedure performed in selected patients with recurrent or locally advanced gynecological cancers. Due to its complexity, careful cardiovascular monitoring and multidisciplinary perioperative management are necessary to ensure patient safety.[47]

7.4 Preoperative Cardiac Evaluation

Before surgery, patients should undergo a detailed cardiovascular assessment, including medical history, physical examination, electrocardiography (ECG), echocardiography, and pacemaker interrogation. Identifying cardiac risk factors before surgery helps reduce perioperative complications.[48]]

7.5 Intraoperative Pacemaker Management

During surgery, electrocautery devices may interfere with pacemaker function. To minimize this risk, bipolar electrocautery should be used whenever possible, continuous ECG monitoring should be maintained, and external pacing or defibrillation equipment should be readily available if needed.[49]

7.6 Postoperative Cardiac Care

Following surgery, pacemaker function should be reassessed, and patients should be monitored for arrhythmias, infection, electrolyte imbalance, and hemodynamic instability. Regular follow-up by both the cardiology and oncology teams helps ensure safe recovery and early detection of complications.[50]

8. Multidisciplinary Management Approach

8.1 Role of the Multidisciplinary Team

The management of pacemaker-dependent patients with gynecological malignancies requires close collaboration among different healthcare professionals. A multidisciplinary team (MDT) helps develop an individualized treatment plan while reducing the risk of cardiovascular and treatment-related complications.[51]

8.2 Role of the Gynecologic Oncologist

The gynecologic oncologist is responsible for cancer diagnosis, staging, treatment planning, and selecting the most appropriate therapeutic approach. Treatment decisions should consider both oncological outcomes and the patient's cardiovascular condition.[52]

8.3 Role of the Cardiologist and Electrophysiologist

Cardiologists evaluate cardiovascular risk before treatment and monitor cardiac function throughout therapy. Electrophysiologists assess pacemaker performance, perform device interrogation, and manage any pacemaker-related complications that may occur during cancer treatment.[53]

8.4 Role of the Radiation Oncologist and Medical Oncologist

The radiation oncologist plans radiotherapy to minimize radiation exposure to the pacemaker, while the medical oncologist selects chemotherapy or targeted therapy with careful consideration of potential cardiotoxic effects. Close coordination between both specialists is essential for safe treatment.[54]

8.5 Patient Follow-up and Long-Term Monitoring

Regular follow-up is important to evaluate treatment response, monitor pacemaker function, detect cardiovascular complications, and identify cancer recurrence. Continuous communication among the multidisciplinary team ensures comprehensive patient care and improves long-term clinical outcomes[55]

Table 3. Management of Pacemaker Depended Patients During Cancer Tharapy

Treatment Stage	Key Management
Before Treatment	ECG, Echocardiography , Pacemaker interrogation
During Radiotherapy	Device shielding , Dose monitoring
During Chemotherap	ECG and electrolyte monitoring
During Surgery	Magnet mode if required ,Bipolar cautery
After Treatment	Device interrogation and regular follow up [56]

9. Clinical Challenges and Management Strategies

9.1 Challenges in Cancer Treatment

Managing gynecological malignancies in pacemaker-dependent patients is clinically challenging because cancer treatment must be balanced with cardiovascular safety. Chemotherapy, radiation therapy, and major surgery may affect cardiac function or interfere with pacemaker performance, making individualized treatment planning essential.[57]

9.2 Pacemaker-Related Challenges

Radiation exposure, electromagnetic interference during surgery, and treatment-related physiological changes may alter pacemaker function. Regular device interrogation before, during, and after treatment helps detect and manage these complications at an early stage.

9.3 Strategies to Reduce Cardiovascular Risk

A comprehensive cardiovascular assessment should be performed before initiating cancer therapy. Appropriate treatment planning, continuous ECG monitoring, periodic echocardiography, pacemaker evaluation, and timely management of cardiovascular risk factors can significantly reduce treatment-related complications.[58]

9.4 Importance of Patient-Centered Care

Every patient has unique clinical characteristics and treatment needs. A patient-centered approach that considers cancer stage, cardiac status, age, comorbidities, and personal preferences helps optimize treatment outcomes while maintaining quality of life.

9.5 Clinical Recommendations

Safe management of pacemaker-dependent patients requires close collaboration between gynecologic oncologists, cardiologists, radiation oncologists, medical oncologists, anesthesiologists, and electrophysiologists. Adherence to current clinical guidelines, regular follow-up, and multidisciplinary decision-making can improve both oncological and cardiovascular outcomes.[59]

10. Drug–Device Interactions in Pacemaker-Dependent Cancer Patients

10.1 Chemotherapy interaction with pacemaker function

Chemotherapeutic agents used in gynecological malignancies can indirectly influence pacemaker performance by altering myocardial electrophysiology rather than directly damaging the device. Electrolyte disturbances such as hypokalemia and hypomagnesemia induced by platinum-based agents (cisplatin, carboplatin) can increase pacing thresholds and predispose to sensing abnormalities and intermittent capture failure.[60]

Taxanes such as paclitaxel have been associated with transient bradyarrhythmias and conduction disturbances, which may complicate interpretation of pacemaker function during therapy. Anthracyclines, although less commonly used in gynecological cancers, are strongly associated with dose-dependent cardiomyopathy and secondary electrical instability.

Therefore, periodic ECG monitoring and device interrogation are recommended during chemotherapy cycles to ensure optimal device function and early detection of pacing irregularities.[61]

10.2 Radiation scatter effects on devices

Radiotherapy remains a cornerstone in cervical and endometrial malignancies, but scatter radiation poses a risk to implanted cardiac devices. Exposure above 2–10 Gy may result in semiconductor damage, software reset, or permanent pacemaker failure. Even lower doses may induce transient malfunction due to cumulative ionizing effects. [62]

The risk is higher in pelvic malignancies where radiation fields may indirectly scatter toward thoracic regions containing pacemakers. Modern techniques such as intensity-modulated radiotherapy (IMRT) and image-guided radiotherapy (IGRT) significantly reduce device exposure and improve safety profiles.

Dose mapping and strict adherence to device shielding protocols are essential to minimize long-term complications. [63]

10.3 Electromagnetic interference (EMI) in OT/ICU

Electromagnetic interference is a well-documented cause of temporary or permanent pacemaker dysfunction in operative and intensive care settings. Monopolar electrocautery is the most common source, capable of causing oversensing, pacing inhibition, or asynchronous pacing behavior. [64]

ICU environments with multiple electrical devices may generate low-grade EMI, potentially affecting sensitive device algorithms in pacemaker-dependent patients. Bipolar cautery, short energy bursts, and proper grounding significantly reduce risk.

Clinical guidelines recommend continuous ECG monitoring and immediate availability of external pacing during high-risk

procedures. .[65]

10.4 MRI safety in pacemaker patients

Magnetic resonance imaging was historically contraindicated in patients with pacemakers due to risks of lead heating, torque forces, and device malfunction. However, MRI-conditional devices have demonstrated safety under controlled conditions. .[66]

Pre-MRI protocols include device interrogation, reprogramming to MRI-safe mode, and continuous monitoring during scanning[24]. Post-scan reassessment ensures restoration of baseline device parameters.

Despite technological advances, non–MRI-conditional devices still carry residual risks, especially in pacemaker-dependent patients. .[67]

10.5 Surgical diathermy risks

Electrosurgical diathermy used in gynecological oncology surgeries can generate electromagnetic fields that interfere with pacemaker function. Monopolar systems are particularly associated with pacing inhibition and inappropriate sensing due to current dispersion. .[68]

Bipolar diathermy is preferred due to localized current flow and reduced EMI risk. Preoperative reprogramming of pacemakers into asynchronous mode is recommended for dependent patients undergoing major oncologic surgery. .[69]

Proper placement of return electrodes away from the device significantly reduces complication rates. .[70]

11. Acute Cardiac Emergencies in Cancer Patients

11.1 Arrhythmias (AF, VT, bradycardia)

Atrial fibrillation is the most common arrhythmia in cancer patients and is frequently triggered by systemic inflammation, chemotherapy toxicity, and electrolyte imbalance. Ventricular tachycardia may occur secondary to QT-prolonging agents or structural myocardial injury. .[71]

Bradyarrhythmias are particularly dangerous in pacemaker-dependent patients, where device malfunction or increased pacing threshold can lead to acute hemodynamic instability. Continuous cardiac monitoring and immediate device interrogation are critical in such cases. .[72]

11.2 Myocarditis (immune therapy related)

Immune checkpoint inhibitors have been associated with immune-mediated myocarditis, a rare but life-threatening complication with mortality rates up to 50% in severe cases. .[73]

Clinical presentation includes chest pain, dyspnea, arrhythmias, and elevated troponin levels. Early recognition and immediate discontinuation of immunotherapy are essential[38]. High-dose corticosteroids remain the first-line treatment. .[74]

11.3 Cardiac tamponade

Malignancy-associated pericardial effusion can progress to cardiac tamponade, particularly in advanced gynecological cancers such as ovarian carcinoma.

Echocardiography remains the diagnostic modality of choice. Emergency pericardiocentesis is life-saving and often required in unstable patients[41]. Radiation-induced pericardial disease is another contributing factor. .[75]

11.4 Thromboembolism in malignancy

Cancer is a well-established hypercoagulable state, increasing the risk of venous thromboembolism (VTE) significantly. Chemotherapeutic agents such as cisplatin and anti-angiogenic drugs like bevacizumab further elevate thrombotic risk. .[76]

Pulmonary embolism remains a leading cause of sudden deterioration in oncology patients and requires prompt anticoagulation therapy balanced against bleeding risk. .[77]

11.5 Sudden cardiac death risk

Sudden cardiac death in gynecological oncology patients is multifactorial, involving chemotherapy-induced cardiotoxicity, arrhythmias, electrolyte imbalance, and device malfunction. .[78]

Pacemaker-dependent patients represent a particularly vulnerable subgroup due to risk of pacing failure or electromagnetic interference during treatment procedures[47]. Multidisciplinary monitoring significantly reduces mortality risk. .[79]

12. Recent Advances

12.1 Advances in Cardio-Oncology

The field of cardio-oncology has progressed significantly in recent years, improving the management of cancer patients with

cardiovascular diseases. .[80] Early cardiac risk assessment, multidisciplinary care, and regular monitoring have contributed to safer cancer treatment and better patient outcomes. .[81]

12.2 Modern Radiation Therapy Techniques

Advanced radiation techniques such as Intensity-Modulated Radiation Therapy (IMRT), Image-Guided Radiation Therapy (IGRT), and Proton Beam Therapy enable more precise delivery of radiation while minimizing exposure to surrounding healthy tissues and implanted pacemakers. These approaches reduce the risk of radiation-related complications. .[82]

12.3 MRI-Conditional Pacemakers and Remote Monitoring

The introduction of MRI-conditional pacemakers has improved diagnostic imaging in cancer patients who require magnetic resonance imaging. .[83] In addition, remote pacemaker monitoring allows continuous assessment of device performance, enabling early detection of abnormalities and timely clinical intervention.[84]

12.4 Artificial Intelligence and Precision Medicine

Artificial intelligence (AI) is increasingly being used to improve cancer diagnosis, treatment planning, and prediction of cardiovascular risk.[85] Precision medicine further supports individualized treatment by considering each patient's clinical profile, helping to optimize both oncological and cardiac outcomes. .[86]

12.5 Future Innovations

Emerging technologies, including advanced cardiac imaging, wearable monitoring devices, and next-generation implantable cardiac devices, are expected to further improve the safety and effectiveness of cancer treatment in pacemaker-dependent patients. .[87] Continued research and technological innovation will strengthen multidisciplinary cardio-oncology care.[88]

13. Future Perspectives

13.1 Development of Evidence-Based Clinical Guidelines

Despite significant advances in cardio-oncology, specific evidence-based guidelines for the management of pacemaker-dependent patients with gynecological malignancies remain limited.[89]Most current recommendations are based on expert opinion or general guidelines for patients with cardiac implantable electronic devices. Future research should focus on developing standardized protocols for cardiovascular assessment, pacemaker management, radiation dose limitations, perioperative care, and long-term follow-up.[90]. Such guidelines will help clinicians make informed decisions and ensure consistent patient care.

13.2 Personalized and Precision Medicine

The future of cancer treatment is moving toward personalized medicine, where therapeutic decisions are tailored according to tumor characteristics, genetic profile, cardiovascular risk factors, and patient-specific clinical conditions. .[91] Individualized treatment planning may reduce cardiotoxicity while maintaining optimal cancer control. Biomarkers and genomic profiling are also expected to play an important role in predicting treatment response and cardiovascular complications. .[92]

13.3 Technological Innovations

Rapid advances in medical technology are expected to improve the safety of cancer treatment in pacemaker-dependent patients. .[93] Modern radiotherapy techniques, MRI-conditional pacemakers, remote device monitoring, wearable cardiac sensors, artificial intelligence (AI), and machine learning can enhance treatment planning, detect complications at an early stage, and support clinical decision-making. These innovations may reduce unnecessary treatment interruptions and improve overall patient outcomes.[94]

13.4 Future Clinical Research

There is a need for large multicenter prospective studies to evaluate the long-term cardiovascular effects of chemotherapy, radiation therapy, and radical surgery in patients with implanted pacemakers.[95]. Future research should also investigate the optimal radiation dose thresholds, strategies to prevent cardiotoxicity, and the effectiveness of multidisciplinary cardio-oncology programs. High-quality clinical evidence will help strengthen future treatment recommendations.[96]

13.5 Strengthening Multidisciplinary Cardio-Oncology Care

The future management of gynecological malignancies will increasingly depend on integrated multidisciplinary care[97]. Close collaboration among gynecologic oncologists, cardiologists, electrophysiologists, radiation oncologists, medical oncologists, anesthesiologists, radiologists, and medical physicists is essential for comprehensive patient management. .[98] Regular communication among specialists, combined with individualized follow-up and patient education, can improve treatment safety, reduce cardiovascular complications, and enhance long-term survival and quality of life. .[99]

Overall, future progress in cardio-oncology will depend on continued research, technological innovation, personalized

treatment strategies, and multidisciplinary collaboration.[100]. These developments have the potential to transform the management of pacemaker-dependent patients with gynecological malignancies and improve both oncological and cardiovascular outcomes.[101]

14. CONCLUSION

Gynecological malignancies remain a major health concern among women worldwide, and their management has become increasingly complex in patients who are dependent on permanent pacemakers. Although multimodal treatment approaches, including chemotherapy, radiation therapy, and radical surgery, have significantly improved cancer survival, they may also increase the risk of cardiovascular complications and interfere with pacemaker function. Therefore, achieving a balance between effective cancer treatment and cardiovascular safety is a key clinical priority.

This review highlights the importance of comprehensive cardiovascular assessment before initiating cancer therapy, careful treatment planning, continuous cardiac monitoring, and regular pacemaker evaluation throughout the treatment course. Modern radiotherapy techniques, improved chemotherapeutic strategies, and advances in perioperative management have substantially enhanced the safety of cancer treatment in this high-risk patient population. However, individualized treatment decisions remain essential because the cardiovascular risk profile varies among patients.[49]

A multidisciplinary cardio-oncology approach involving gynecologic oncologists, cardiologists, electrophysiologists, radiation oncologists, medical oncologists, anesthesiologists, radiologists, and medical physicists plays a central role in optimizing patient care. Effective communication among these specialists facilitates timely identification of complications, appropriate modification of treatment plans, and improved clinical outcomes.

Despite remarkable progress in both oncology and cardiovascular medicine, important knowledge gaps still exist regarding the optimal management of pacemaker-dependent patients with gynecological malignancies. Future research should focus on large prospective studies, development of evidence-based clinical guidelines, and integration of emerging technologies such as artificial intelligence, remote cardiac monitoring, and precision medicine into routine clinical practice

REFERENCES

1. Suneja G, Viswanathan A. Gynecologic Malignancies. *Hematol Oncol Clin North Am.* 2020;34(1):71-89. doi:10.1016/j.hoc.2019.08.018
2. Blair AR, Casas CM. **Gynecologic cancers.** *Prim Care.* 2009 Mar;36(1):115-130, ix. doi:10.1016/j.pop.2008.10.001. PMID: 19231605.
3. Bray f, laversanne m, sung h, et al. global cancer statistics 2022: globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries. ca cancer j clin. 2024;74(3):229-263. doi:10.3322/caac.21834
4. Salehi AM, Shahbazi F, Garavand R, Kamkari S, Jenabi E**.** *BMC Women's Health.* 2025;25:596. doi:10.1186/s12905-025-03961-3. PMID: 40999424.
5. Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2024 (CA: A Cancer Journal for Clinicians).
6. Lyon AR, Lopez-Fernandez T, Couch LS, et al. 2022 ESC Guidelines on cardio-oncology. Eur Heart J. 2022;43(41):4229-4361.
7. Parashar S, Akhter N, Paplomata E, et al. Cancer Treatment-Related Cardiovascular Toxicity in Gynecologic Malignancies: JACC: Cardio Oncology State-of-the-Art Review. JACC CardioOncol. 2023;5(2):159-173.
8. Curigliano G, Lenihan D, Fradley M, et al. Management of cardiac disease in cancer patients throughout oncological treatment: ESMO Consensus Recommendations. Ann Oncol. 2020;31(2):171-190.
9. Hurkmans CW, Knegjens JL, Oei BS, et al. *Radiat Oncol.* 2012;7:198. doi:10.1186/1748-717X-7-198.
10. Qiao H, Jiang F, Ning P, et al. *Acta Cardiol Sin.* 2023;39(6):807-816. doi:10.6515/AC .202311_39(6).20230828A
11. Zamorano JL, Lancellotti P, Rodriguez Muñoz D, et al.2016 ESC Position Paper on cancer treatments and cardiovascular toxicity and prevention**.** *Eur Heart J.* 2016;37(36):2768–2801
12. Plana JC, Galderisi M, Barac A, et al.Expert consensus for multimodality imaging evaluation during cancer therapy**.** *J Am Soc Echocardiogr.* 2014;27(9):911–939.
13. WHO. Cervical cancer: key facts and global guidelines update. *World Health Organization (WHO).* 2023
14. Colombo N, Sessa C, du Bois A, et al.ESMO-ESGO consensus conference recommendations on ovarian cancer. *Ann Oncol.* 2019;30(5):672–705.
15. Concin N, Creutzberg CL, Vergote I, et al.ESMO-ESGO-ESTRO consensus guidelines for endometrial cancer. *Int J Gynecol Cancer.* 2021;31(1):12–39.

16. ESGO guidelines for the management of vulvar cancer**.** *Int J Gynecol Cancer.* 2020;30(5):652–670

17. NCCN Clinical Practice Guidelines in Oncology.Cervical Cancer / Ovarian Cancer / Endometrial Cancer / Uterine Neoplasms (latest versions). National Comprehensive Cancer Network (NCCN). 2025.

18. Zaremba T, Jakobsen AR, Søgaard M, Thøgersen AM, Johansen MB, Madsen LB. Radiotherapy in patients with pacemakers and implantable cardioverter-defibrillators: A literature review. Europace. 2016;18(4):479-491. doi:10.1093/europace/euv300.

19. Virani SA, Dent S, Brezden-Masley C, et al.Canadian Cardiovascular Society guidelines for evaluation and management of cardiovascular complications of cancer therapy.*Can J Cardiol.* 2016;32(7):831–841.

20. Lyon AR, López-Fernández T, Couch LS, et al.2022 ESC Guidelines on cardio-oncology developed in collaboration with EHA, ESTRO and IC-OS. *Eur Heart J.* 2022;43(41):4229–4361.

21. Kusumoto FM, Schoenfeld MH, Barrett C, et al. 2018 ACC/AHA/HRS guideline on bradycardia and conduction delay.*Circulation.* 2019;140(8):e382–e482.

22. Glikson M, Nielsen JC, Kronborg MB, et al.2013 ESC pacing and CRT guidelines. *Eur Heart J.* 2013;34(29):2281–2329.

23. Querleu D, et al. Radical hysterectomy and pelvic surgery classification. Int J Gynecol Cancer. 2017.

24. Zaremba T, Jakobsen AR, Søgaard M, et alRadiation effects on pacemakers/ICDs. *Europace.* 2016;18:479–491.https://doi.org/10.1093/europace/euv135

25. Grant JD, Kudchadker RJ, Palta M, et al.Radiotherapy in patients with cardiac devices. *Int J Radiat Oncol Biol Phys.* 2015;91(5):973–980.https://doi.org/10.1016/j.ijrobp.2015.01.00

26. Yeh ETH, Bickford CL. Cardiovascular complications of cancer therapy: Incidence, pathogenesis, detection, and management. J Am Coll Cardiol. 2009;53(24):2231-2247. doi:10.1016/j.jacc.2009.02.050

27. Mutch DG, et al. Surgical management of advanced gynecologic malignancies. Obstet Gynecol. 2019.

28. Indik JH, Gimbel JR, Abe H, et al. 2023 HRS Expert Consensus Statement on magnetic resonance imaging and radiation exposure in patients with cardiovascular implantable electronic devices. Heart Rhythm. 2023

29. Minotti G, Menna P, Salvatorelli E, Cairo G, Gianni L. Anthracyclines: Molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev. 2004;56(2):185-229. doi:10.1124/pr.56.2.6.

30. Totzeck M, Mincu RI, Rassaf T. Cardiovascular adverse events in patients with cancer treated with bevacizumab: A meta-analysis. J Am Heart Assoc. 2017;6:e006278.

31. Darby SC, Ewertz M, McGale P, et al. Risk of ischemic heart disease in women after radiotherapy for breast cancer. N Engl J Med. 2013;368(11):987-998. doi:10.1056/NEJMoa1209825.

32. Benedict SH, Yenice KM, Followill D, et al. Stereotactic body radiation therapy: The report of AAPM Task Group 101. Med Phys. 2010;37(8):4078-4101. doi:10.1118/1.3438081.

33. Viswanathan AN, Beriwal S, De Los Santos JF, et al. American Brachytherapy Society consensus guidelines for locally advanced carcinoma of the cervix. Brachytherapy. 2012;11(1):33-46. doi:10.1016/j.brachy.2011.07.002.

34. Zaremba T, Jakobsen AR, Søgaard M, Thøgersen AM, Johansen MB, Madsen LB. Radiotherapy in patients with pacemakers and implantable cardioverter-defibrillators: A literature review. Europace. 2016;18(4):479-491. doi:10.1093/europace/euv300.

35. European Society of Cardiology. 2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery. Eur Heart J. 2022.

36. Crossley GH, Poole JE, Rozner MA, et al. The Heart Rhythm Society (HRS)/American Society of Anesthesiologists Expert Consensus Statement on the perioperative management of patients with cardiac implantable electronic devices. Heart Rhythm. 2011;8(7):1114-1154

37. Herrmann J. Vascular toxic effects of cancer therapies. *Nat Rev Cardiol.* 2020;17(8):503–522. doi:10.1038/s41569-020-0348-1.

38. European Society of Cardiology. 2022 ESC Guidelines on cardio-oncology. *Eur Heart J.* 2022;43(41):4229–4361

39. Yeh ETH, Bickford CL. Cardiovascular complications of cancer therapy: Incidence, pathogenesis, diagnosis, and management. *J Am Coll Cardiol.* 2009;53(24):2231–2247.

40. Swain SM, Whaley FS, Ewer MS. Congestive heart failure in patients treated with doxorubicin: A retrospective

analysis of three trials. *Cancer.* 2003;97(11):2869–2879.

41. Totzeck M, Mincu RI, Rassaf T. Cardiovascular adverse events in patients with cancer treated with bevacizumab: A meta-analysis of more than 20,000 patients. *J Am Heart Assoc.* 2017;6:e006278.
42. Plana JC, et al. Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy. J Am Soc Echocardiogr. 2014.
43. Herrmann J. Adverse cardiac effects of cancer therapies: cardiotoxicity and arrhythmia. Nat Rev Cardiol. 2020.
44. Cardiotoxicity of anticancer drugs: molecular mechanisms and strategies for cardioprotection. Front Cardiovasc Med. 2022.
45. Cardiotoxicity of anti-cancer drugs: cellular mechanisms and clinical implications. Front Cardiovasc Med. 2023.
46. Cancer therapy-induced cardiotoxicity: mechanisms and clinical implications. 2025.
47. Chemotherapy-induced cardiotoxicity: mechanisms, detection and management. 2025.
48. Mechanisms of cardiotoxicity of cancer chemotherapeutic agents. 2016.
49. Cardiotoxicity of chemotherapy and targeted agents. 2021.
50. Chemotherapy-induced cardiotoxicity: overview of the molecular and biochemical mechanisms. 2015.
51. Chemotherapy-induced cardiotoxicity. 2013.
52. Pathophysiological mechanisms of cardiotoxicity in chemotherapy. 2020.
53. Cardiotoxicity induced by traditional chemotherapy: mechanisms and mitigation strategies. 2026.
54. Shah NR, et al. Cardio-oncology in clinical practice: contemporary approaches to surveillance and management. Eur Heart J. 2021.
55. Armenian SH, et al. Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: ASCO guideline. J Clin Oncol. 2017.
56. Cardinale D, et al. Anthracycline-induced cardiomyopathy: clinical relevance and monitoring. J Am Coll Cardiol. 2010.
57. Ewer MS, Lippman SM. Type II chemotherapy-related cardiac dysfunction: time to recognize a new entity. J Clin Oncol. 2005.
58. Feldman AM, Valentijn AJ. Cardiotoxicity of cancer therapeutics: mechanisms and clinical consequences. Circulation. 2016.
59. de Azambuja E, et al. Trastuzumab-related cardiac dysfunction: risk factors and management. J Clin Oncol. 2010.
60. Suter TM, et al. Trastuzumab-associated cardiac adverse effects in clinical trials. J Clin Oncol. 2007.
61. Moik F, et al. Cancer therapy-related arrhythmias. JACC CardioOncol. 2021.
62. Lenihan DJ, et al. Cardiotoxicity monitoring in oncology: biomarkers and imaging. J Am Coll Cardiol. 2018.
63. Cardinale D, et al. Role of troponin in predicting chemotherapy-induced cardiotoxicity. Circulation. 2000.
64. Abdel-Qadir H, et al. Biomarkers for early detection of cardiotoxicity in cancer therapy. Eur Heart J. 2022.
65. Thavendiranathan P, et al. Echocardiography in cardiac surveillance during cancer therapy. J Am Coll Cardiol. 2017.
66. Plana JC, et al. Imaging cardiac function during and after cancer therapy. Eur Heart J Cardiovasc Imaging. 2018.
67. Yeh ETH, Bickford CL. Cardiovascular complications of cancer therapy: incidence, mechanisms, and management. Circulation. 2009.
68. Bansal N, et al. Cancer therapy-related cardiac dysfunction. Heart. 2020.
69. Vejpongsa P, Yeh ETH. Prevention of anthracycline-induced cardiotoxicity: challenges and opportunities. J Am Coll Cardiol. 2014.
70. Curigliano G, et al. Management of cardiac disease in cancer patients throughout oncological treatment. ESMO consensus. 2020.
71. Lyon AR, et al. Baseline cardiovascular assessment before cancer therapy. Eur J Heart Fail. 2020.
72. Armenian SH, et al. Cardiovascular screening and surveillance in cancer patients. J Clin Oncol. 2022.

73. Dobson R, et al. Monitoring for cardiotoxicity in patients receiving cancer therapy. BMJ. 2019.
74. Eliott AD, et al. Pacemaker and ICD management during surgery. Anaesthesia. 2018.
75. Crossley GH, et al. 2011 HRS/ASA expert consensus statement on perioperative management of patients with pacemakers and ICDs. Heart Rhythm. 2011.
76. HRS/ASA perioperative CIED management updates. Heart Rhythm. 2020.
77. Leung LW, et al. Electrocautery and implanted cardiac devices: perioperative precautions. Anesth Analg. 2019.
78. Madigan JD, et al. Management of cardiac implantable electronic devices during procedures. Pacing Clin Electrophysiol. 2017.
79. Zecchin M, et al. Surgery in pacemaker-dependent patients: practical management strategies. Europace. 2021.
80. Stone ME, et al. Intraoperative management of the patient with a pacemaker. Surg Clin North Am. 2020.
81. Misiri J, et al. Electromagnetic interference and implanted cardiac devices. Mayo Clin Proc. 2012.
82. Kanal E, et al. MRI safety in patients with pacemakers and ICDs. Radiology. 2017.
83. Nazarian S, et al. MRI in patients with non-MRI-conditional devices. N Engl J Med. 2017.
84. Russo RJ, et al. Assessing the risks of MRI in patients with cardiac devices. Circulation. 2017.
85. HRS expert consensus on MRI and CIEDs. Heart Rhythm. 2017.
86. Varma N, et al. Remote monitoring of cardiac devices: clinical utility. J Am Coll Cardiol. 2018.
87. Singh JP, et al. Radiation exposure and pacemaker malfunction. Heart Rhythm. 2012.
88. Hurkmans CW, et al. Recommendations for radiotherapy in patients with pacemakers. Radiother Oncol. 2012.
89. Gossman MS, et al. Device management during radiotherapy. Pract Radiat Oncol. 2017.
90. Miften M, et al. AAPM TG-203: management of radiotherapy patients with implanted cardiac devices. Med Phys. 2019.
91. Marbach JR, et al. The tolerance of pacemakers to ionizing radiation. Int J Radiat Oncol Biol Phys. 1994.
92. Zaremba T, et al. Cardiac implantable devices and modern radiotherapy techniques. Clin Oncol. 2020.
93. Grant JD, et al. Interference between radiotherapy and pacemakers. J Clin Oncol. 2015.
94. Brambs CE, et al. Pacemakers in oncology patients: radiation safety and monitoring. Strahlenther Onkol. 2021.
95. Shah AD, et al. Device malfunction during cancer therapy. JACC Clin Electrophysiol. 2022.
96. Perioperative management of implanted cardiac devices in major surgery. Br J Anaesth. 2019.
97. Mazur A, et al. Electrosurgery and cardiac implantable devices. Clin Cardiol. 2018.
98. Ellenbogen KA, et al. Clinical cardiac pacing, defibrillation, and resynchronization therapy. 2019.
99. Connor JP, et al. Radical hysterectomy in early cervical cancer: surgical standards and perioperative assessment. Gynecol Oncol. 2018.
100. Berek JS, et al. Ovarian cancer cytoreductive surgery: principles and outcomes. Int J Gynecol Cancer. 2020.
101. Höckel M, et al. Pelvic exenteration for recurrent gynecologic malignancies. Lancet Oncol. 2016.